

30 September 2024

**Kromek Group plc**  
("Kromek" or the "Group")

**Update on Full Year Results**

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, gives notice that, further to the Group's trading update of 29 May 2024 (the "Trading Update") in which it stated it expected to release its full year results in September 2024, the Group now expects to announce its final results for the year ended 30 April 2024 during the second half of October.

The Group is experiencing increasing commercial and strategic momentum and continues to pursue further initiatives across the business. As noted in the Trading Update, Kromek expects to report positive EBITDA for FY 2024, ahead of market expectations. This reflects an anticipated improvement in gross margin due to the product mix sold combined with the Group exerting continued tight cost control whilst driving operational efficiencies, particularly within its advanced imaging manufacturing process.

Further details will be provided in the Group's final results announcement.

**For further information, please contact:**

**Kromek Group plc**

Arnab Basu, CEO

+44 (0)1740 626 060

Paul Farquhar, CFO

**Cavendish Capital Markets Limited (Nominated Adviser and Broker)**

Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance

+44 (0)20 7220 0500

Tim Redfern - ECM

Michael Johnson/Tamar Cranford-Smith - Sales

**Gracechurch Group (Financial PR)**

Harry Chathli/Claire Norbury/Henry Gamble

+44 (0)20 4582 3500

**Kromek Group plc**

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical, security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defense and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

Further information is available at [www.kromek.com](http://www.kromek.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDFFFLLATIAFIS